Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy, largely driven by a dense desmoplastic stroma and a strongly immunosuppressive and cold tumor microenvironment (TME). Moreover, aberrant neural remodeling and increased nerve density further fuel disease progression, highlighting the key role of nerve-tumor crosstalk. In this regard, semaphorin signaling, classically involved in axon guidance, has emerged as an important modulator of the PDAC microenvironment. In particular, Semaphorin 3A (Sema3A) was shown to normalize tumor vasculature and restrain PDAC growth when administered exogenously. Hence, we engineered a mutant Sema3A isoform (Mut-Sema3A) that binds Plexin A4 with high affinity, independently of its co-receptor Neuropilin-1, achieving stronger tumor growth inhibition and suppression of liver metastases, along with improved chemotherapy delivery and efficacy. To investigate the effects of Mut-Sema3A on the microenvironment, we performed scRNA-seq on tumors from a syngeneic orthotopic mouse model of PDAC after depletion of malignant cells. Importantly, we demonstrated that treatment with Mut-Sema3A led to an increase in CD8⁺ T cells, as further confirmed by immunofluorescence analysis. To further explore the immune impact of Mut-Sema3A, we examined tertiary lymphoid structures (TLSs), key orchestrators of anti-tumor immunity. Notably, confocal analyses revealed that Mut-Sema3A treatment reduced TLS number and volume while enriching activated CD8⁺ T, CD4⁺ T, and plasma cells, indicating that Mut-Sema3A reprograms TLSs, promoting a functionally mature state capable of driving effective anti-tumor immunity. In parallel, considering the role of semaphorins as axon-repellent cues and the emerging importance of tumor-associated nerves in PDAC, and based on recent findings demonstrating that sensory nerves prevent lymphocyte infiltration and impair TLS maturation and function, we started to investigate the effect of Mut-Sema3A on PDAC innervation by employing human iPSC-derived neurons. Notably, Mut-Sema3A induced dose-dependent cytotoxicity and apoptosis in human neurons and markedly reduced neurite outgrowth. Next, we evaluated the impact of cancer cells on neurons under indirect co-culture conditions, observing that PDAC cells promoted a significant increase in neurite growth compared with neurons cultured alone. Remarkably, the addition of Mut-Sema3A to the co-culture system significantly reduced this PDAC-induced neuronal projection, suggesting its ability to counteract cancer-driven neuronal remodeling. To further explore tumor-nerve crosstalk, we then examined the influence of neurons on cancer cell behavior. Consistently, exposure to neuron-conditioned media significantly enhanced PDAC cell survival and proliferation, indicating that neurons within the tumor microenvironment could actively support pancreatic cancer growth. Subsequently, we observed that Mut-Sema3A reduced tumor burden is associated with normalization of tumor-associated nerves, in a preclinical orthotopic model of pancreatic cancer. In fact, confocal microscope analysis revealed that in vivo treatment with Mut-Sema3A efficiently impaired tumor hyperinnervation. These data suggest that Mut-Sema3A may limit tumor progression by restoring pancreatic innervation patterns similar to healthy tissue, in addition to its effects on the tumor microenvironment, including promoting TLS maturation. Overall, our findings demonstrate that Mut-Sema3A can hinder PDAC progression by reducing tumor hyperinnervation and promoting a more immunologically active microenvironment, with these two mechanisms potentially acting in concert or influencing each other to collectively limit tumor growth and disease progression.
Sema3A regulates tumor-associated neural remodeling and promotes tertiary lymphoid structures (TLSs) activation to restrain PDAC progression
Bertalmio NFirst
;Brundu S;Nicorvo E;Boido M;Vercelli A;Giraudo E
Last
2026-01-01
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy, largely driven by a dense desmoplastic stroma and a strongly immunosuppressive and cold tumor microenvironment (TME). Moreover, aberrant neural remodeling and increased nerve density further fuel disease progression, highlighting the key role of nerve-tumor crosstalk. In this regard, semaphorin signaling, classically involved in axon guidance, has emerged as an important modulator of the PDAC microenvironment. In particular, Semaphorin 3A (Sema3A) was shown to normalize tumor vasculature and restrain PDAC growth when administered exogenously. Hence, we engineered a mutant Sema3A isoform (Mut-Sema3A) that binds Plexin A4 with high affinity, independently of its co-receptor Neuropilin-1, achieving stronger tumor growth inhibition and suppression of liver metastases, along with improved chemotherapy delivery and efficacy. To investigate the effects of Mut-Sema3A on the microenvironment, we performed scRNA-seq on tumors from a syngeneic orthotopic mouse model of PDAC after depletion of malignant cells. Importantly, we demonstrated that treatment with Mut-Sema3A led to an increase in CD8⁺ T cells, as further confirmed by immunofluorescence analysis. To further explore the immune impact of Mut-Sema3A, we examined tertiary lymphoid structures (TLSs), key orchestrators of anti-tumor immunity. Notably, confocal analyses revealed that Mut-Sema3A treatment reduced TLS number and volume while enriching activated CD8⁺ T, CD4⁺ T, and plasma cells, indicating that Mut-Sema3A reprograms TLSs, promoting a functionally mature state capable of driving effective anti-tumor immunity. In parallel, considering the role of semaphorins as axon-repellent cues and the emerging importance of tumor-associated nerves in PDAC, and based on recent findings demonstrating that sensory nerves prevent lymphocyte infiltration and impair TLS maturation and function, we started to investigate the effect of Mut-Sema3A on PDAC innervation by employing human iPSC-derived neurons. Notably, Mut-Sema3A induced dose-dependent cytotoxicity and apoptosis in human neurons and markedly reduced neurite outgrowth. Next, we evaluated the impact of cancer cells on neurons under indirect co-culture conditions, observing that PDAC cells promoted a significant increase in neurite growth compared with neurons cultured alone. Remarkably, the addition of Mut-Sema3A to the co-culture system significantly reduced this PDAC-induced neuronal projection, suggesting its ability to counteract cancer-driven neuronal remodeling. To further explore tumor-nerve crosstalk, we then examined the influence of neurons on cancer cell behavior. Consistently, exposure to neuron-conditioned media significantly enhanced PDAC cell survival and proliferation, indicating that neurons within the tumor microenvironment could actively support pancreatic cancer growth. Subsequently, we observed that Mut-Sema3A reduced tumor burden is associated with normalization of tumor-associated nerves, in a preclinical orthotopic model of pancreatic cancer. In fact, confocal microscope analysis revealed that in vivo treatment with Mut-Sema3A efficiently impaired tumor hyperinnervation. These data suggest that Mut-Sema3A may limit tumor progression by restoring pancreatic innervation patterns similar to healthy tissue, in addition to its effects on the tumor microenvironment, including promoting TLS maturation. Overall, our findings demonstrate that Mut-Sema3A can hinder PDAC progression by reducing tumor hyperinnervation and promoting a more immunologically active microenvironment, with these two mechanisms potentially acting in concert or influencing each other to collectively limit tumor growth and disease progression.| File | Dimensione | Formato | |
|---|---|---|---|
|
Abstract Bertalmio Nicolò Pancreatic Cancer Conference.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
65.4 kB
Formato
Adobe PDF
|
65.4 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



